Intragastric Balloon-Induced Satiety is Not Mediated by Modification in Fasting or Postprandial Plasma Ghrelin Levels in Morbid Obesity
- 146 Downloads
The BioEnterics Intragastric Balloon (BIB) has been proposed as an adjuvant therapy for the short-term treatment of obesity. The temporal pattern of BIB-induced satiety and whether this effect is mediated by modification of ghrelin levels is unknown.
Patients with treatment-resistant morbid obesity were invited to participate in a randomized, double-blind, sham-controlled trial of 4-month duration. Anthropometric and biochemical parameters, estimation of energy intake, and pre- and postprandial evaluation of satiety were required monthly. Ghrelin response after a standard mixed meal was scheduled prior to and 4 weeks after the endoscopic procedure.
21 out of 22 enrolled patients completed the study (17 women, 5 men; 35.9 ±–.9 years; BMI 50.4 ±–.8 kg/m2). Pre-intervention weight decreased from 143.8 ±–1.2 kg to 131.1 ±–2.6 kg in Group Balloon (P–lt;–.001) and from 138.8 ±–4.5 kg to 129.9 ±–5.6 kg in Group Sham (P–lt;–.01) at the end of the study. Weight loss was not significantly different in Group Balloon and Group Sham at any time-point of the follow-up. Only patients from Group Balloon showed a temporary increased pre- and postprandial satiety, which was maximal at 4 weeks after the intervention. Total area under the curve, fasting and postprandial plasma ghrelin were not significantly different between groups at inclusion or 4 weeks after follow-up. No correlation was found between any of the satiety scores at any time-point with their comparable ghrelin levels.
BIB induces a temporary sense of satiety in morbidly obese patients which is not mediated by modification of fasting or postprandial levels of plasma ghrelin.
Key wordsMorbid obesity intragastric balloon satiety ghrelin bariatric surgery
- 18.Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Draft Statement. Obes Surg 1991; 1: 257–5.Google Scholar
- 19.SEEDO–000 consensus for the evaluation of overweight and obesity and the establishment of criteria for therapeutic intervention. Sociedad Espanola para el Estudio de la Obesidad. Med Clin (Barc) 2000; 115: 587–7.Google Scholar
- 20.Romero H, Martinez-Brocca MA, Pereira JL, Garcia-Luna PP. Pharmacological treatment of obesity. Rev Esp Obes 2005; 3: 13–5.Google Scholar
- 22.Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–7.Google Scholar
- 23.Benjamin SB, Maher KA, Cattau EL et al. A doubleblind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterol 1988; 95: 581–.Google Scholar
- 24.Meshkinpour H, Hsu D, Farivar S. Effect of gastric bubble as a weight reduction device: a controlled crossover study. Gastroenterol 1988; 95: 589–2.Google Scholar